Cancer treatment reviews · 2025
KELIM score: A marker of chemosensitivity in ovarian cancer.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ambrosino Federica Adele, Pisano Carmela, Napoli Marilena Di, Ventriglia Jole, Tambaro Rosa, Rossetti Sabrina, Passarelli Anna, Cavalcanti Ernesta, Cecio Rossella De, Fiore Francesco, Setola Sergio Venanzio, Troiani Teresa, Lobianco Lorenzo, Perri Erica, Lamia Mariarosaria, Calvanese Gabriele, Pignata Sandro, Cecere Sabrina Chiara
Аннотация
Ovarian cancer is the gynecological cancer with the worst prognosis and the highest mortality rate, primarily because 75% of patients are diagnosed with advanced FIGO stage III-IV disease. About 50% of patients are now treated with neoadjuvant chemotherapy followed by interval debulking surgery. In that context, there is a need for accurate predictors of tumor primary chemosensitivity, as it may impact the feasibility of subsequent interval debulking surgery. The cancer antigen 125 ELIMination rate constant K (KELIM) score, a modeled kinetic parameter, is a potential marker of tumor chemosensitivity in patients with ovarian cancer treated with adjuvant or neoadjuvant chemotherapy before interval debulking surgery. This review aims to provide a comprehensive overview of potential predictive factors for response to platinum therapy, focusing on the KELIM score, a marker increasingly used in clinical practice.